Section 3 of 6
Product information and disease description
132 evidence topics · 38 sources
Product description
Phase of product development
Regulatory status: Approved; BLA resubmitted May 2026 and approved July 2026
Launch: Anticipated before the end of 2026
Regulatory history: first Complete Response Letter
Regulatory history: NORSE EIGHT trial, second and third Complete Response Letters
Regulatory history: resubmission acceptance and final approval
Regulatory history: European Union and United Kingdom approval and launch
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Outlook Therapeutics
Generic and brand names, therapeutic class
Dosage forms and strengths
Storage and handling
Composition
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
- Price basis: U.S. wholesale acquisition cost of $485 per vial, established by Outlook Therapeutics on September 16, 2026; each carton holds one 1.25 mg single-dose vial. No average sales price or product-specific HCPCS payment limit had been published as of November 17, 2026.
- Dosing basis: 1.25 mg (one vial) per treated eye by intravitreal injection once monthly (approximately 28 days), the only dosing interval the prescribing information states; each vial treats a single eye, and a second eye requires a separate vial.
- Base case: one eye treated monthly, $485 per vial × 12 injections per year = $5,820 per year; ÷ 12 = $485 per month.
- Range: $5,820 to $12,610 per year ($485 to $1,051 per month). The upper bound is both eyes treated every 28 days: 2 vials × $485 × 13 injections per year = $12,610 per year; ÷ 12 = $1,051 per month. Intermediate values are one eye every 28 days ($485 × 13 = $6,305 per year; $525 per month) and both eyes monthly (2 × $485 × 12 = $11,640 per year; $970 per month).
- Rationale for the range: the label defines monthly as approximately 28 days, which yields 12 to 13 injections per year; bilateral disease doubles the number of vials because the label restricts each vial to one eye; the label states no loading phase, extended interval, or dose reduction, so less frequent dosing falls outside the labeled regimen and is not included.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Average sales price
No evidence found.
American hospital formulary service (AHFS), or other drug classification
No evidence found.
Indication
Pharmacology
Mechanism of action
Mechanism of action
Pharmacodynamics
Central foveal thickness as a pharmacodynamic marker
Pharmacokinetics
Systemic pharmacokinetics after intravitreal injection
Immunogenicity
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Contraindications
Warning: endophthalmitis and retinal detachments
Warning: increases in intraocular pressure
Adverse reactions: clinical trial exposure and most common reaction
Special populations
Pregnancy
Lactation
Females and males of reproductive potential
Drug/Drug, drug/disease interactions
Effects of other drugs on bevacizumab-vikg
No evidence found.
Effects of bevacizumab-vikg on other drugs
No evidence found.
Dosing and administration
Dosage
Recommended dose and dosing interval
Administration
Required devices and preparation
Injection procedure and post-injection monitoring
Access and distribution
Pre-launch preparation and planned launch timing
Reimbursement coding and payer access strategy
Co-prescribed/Concomitant therapies
No evidence found.
Effect of bevacizumab-vikg on quality measures
No evidence found.
Product comparison
NORSE TWO: LYTENAVA versus ranibizumab, dosing regimens and primary endpoint at Month 11
NORSE TWO: patients gaining 15 or more ETDRS letters at 11 months
| Field | LYTENAVA 1.25 mg once monthly (N = 113) | Ranibizumab 0.5 mg once monthly x 3 months then every 3 months (N = 115) |
|---|---|---|
| Number of subjects, n/N (%) | “45/108 (41.7)” | “24/104 (23.1)” |
NORSE TWO: risk difference between LYTENAVA and ranibizumab
NORSE EIGHT: LYTENAVA versus ranibizumab, non-inferiority at Week 8
Comparison with unapproved compounded bevacizumab
Market size and competitive landscape
Place of product in therapy
Disease description
Definition and etiology
Definition of age-related macular degeneration
Dry and wet forms of AMD
Neovascular AMD as a distinct clinical entity
Etiology: age as the leading risk factor
Etiology: family history, race, and smoking
Anatomic basis: the retinal pigment epithelium, Bruch's membrane, and drusen
“Damage to the retinal pigment epithelium (RPE) is considered to be a hallmark of AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Age‐related structural abnormalities within Bruch's membrane have also been associated with AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The AMD spectrum spans early‐stage AMD, during which drusen, pigment epithelial detachment (PED) and vitelliform lesions are observed, to late stage AMD, with choroidal neovascularization (CNV, neovascular AMD) or geographic atrophy (GA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Neovascular age-related macular degeneration
Incidence by age group
“In the age group of 75–84 years, the incidence increased 1.2-fold from 300 in 2006 to 366 in 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The increase in the age group of 85–96 years was 2.4-fold from 200 in 2006 to 471 in 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Neovascular age-related macular degeneration
Prevalence in a population-based cohort
“The prevalence of nAMD was 862 (/100,000 inhabitants) (95% CI 821–906) in adults aged 44–96 years in 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the oldest 75–84 and 85–96 age categories the nAMD prevalence was 2865/100,000 (3%, 95% CI 2665–3079) and 2620/100,000 (3%, 95% CI 2323–2956), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States prevalence among Medicare beneficiaries
United States burden estimates
Natural history, survival, and mortality
Untreated disease course
“Prior to the anti-VEGF era, the clinical manifestation of the natural history of nAMD was the formation of a disciform scar and blindness” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AMD leads to blindness when left untreated, due to the development of atrophy and/or disciform scar.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Magnitude of untreated vision loss
“ranibizumab not only prevented loss of vision in nAMD treatment-naïve patients (the natural history for these patients), but also, and for the first time ever in this disease, that their vision could recover, as shown by the 7.2 letters gained on average in the ranibizumab 0.5 mg dose group (the dose subsequently marketed) versus an average loss of 10.4 letters by the sham group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality attributable to neovascular AMD
No evidence found.
Pathophysiology
Progression from early disease to neovascular disease
“The AMD spectrum spans early‐stage AMD, during which drusen, pigment epithelial detachment (PED) and vitelliform lesions are observed, to late stage AMD, with choroidal neovascularization (CNV, neovascular AMD) or geographic atrophy (GA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Amsler grid self-monitoring
“The Amsler grid consists of horizontal and vertical lines intersecting at a central fixation point.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the patient assesses whether the lines are parallel or show distortion (metamorphopsia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optical coherence tomography angiography
“Optical coherence tomography angiography (OCTA) is a non-invasive imaging technique that allows visualization of retinal and choroidal blood vessels by detecting motion contrast caused by blood flow.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike traditional dye-based angiographic methods, such as fluorescein angiography (FA) or indocyanine green angiography (ICGA), OCTA does not require intravenous contrast agents and can capture volumetric data within seconds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home optical coherence tomography as an adjunct to office-based diagnosis
Clinical presentation - signs and symptoms
Visual symptoms: central vision blur and distortion
Vascular signs: leaking, abnormal blood vessels
Long-term morbidity
Anxiety and depression
“Clinically significant severity of depression symptoms was found in 4.2% of patients, mild manifestations of depression were found in 8.3%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“79.2% demonstrated moderate reactive anxiety; 12.5% of the subjects had a low level of reactive anxiety. 81.7 % of the respondents were subject to moderate and high personal anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progressive fibrotic scarring
Burden of Neovascular age-related macular degeneration
Humanistic burden and health-related quality of life
Emotional burden of injection visits
“Patients reported that they were nervous or struggled to sleep prior to treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“33.1% of patients reported to be stressed and 15.4% struggled to sleep” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients reported the treatment as uncomfortable (54.6%) or as somewhat painful (26.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Annual per-patient cost
“We estimated an annual all-cause cost for patients with nAMD of $24,520 per patient” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“newly diagnosed patients incurred slightly lower costs ($18,943)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outpatient and injection-related resource use
“Mean (SD) annual nAMD-related outpatient burden was 6.6 (4.8) visits overall” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall mean (SD) annual anti-VEGF–related outpatient visit burden was 3.9 (4.2) visits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost by disease activity status
“The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD = $11,612]) compared with the inactive CNV ($2,406 [SD = $5,510]) and inactive scar ($1,198 [SD = $3,035]) groups (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Neovascular age-related macular degeneration on families
Lost work productivity and wages
“Mean wages lost due to impaired work productivity ranged from $1,395 to $55,180.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean wages lost due to unemployment ranged from $22,314 USD to $58,886 USD a year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unemployment associated with AMD-related vision loss
Caregiver work absence and added household expense
“22% requiring a caregiver to take time off from work for transportation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The financial burden of AMD is further exacerbated by additional expenses such as transportation costs, costs for caregivers, and healthcare costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Not applicable.
Approaches to treatment
Current treatment options and standard of care
Anti-VEGF monoclonal antibodies and antibody fragments
Ranibizumab mechanism of action
Ranibizumab indication and dosing for wet AMD
VEGF trap fusion proteins
Aflibercept indication and dosing for wet AMD
Bispecific Anti-VEGF/Angiopoietin-2 antibodies
Faricimab indication and extended dosing intervals
Anti-VEGF biosimilars
Ranibizumab biosimilars
Anticipated cost savings from biosimilars
Agents included in current comparative evidence
Off-label compounded bevacizumab
Origin of off-label use
“ophthalmologists began treating neovascular AMD with off-label use of bevacizumab (Avastin, Genentech), since the drug had a target specificity similar to that of ranibizumab and was available at low cost.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparative efficacy versus ranibizumab (CATT trial)
“Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Repackaging and contamination risk
“During March 6–8, 2013, four patients with age-related macular degeneration received a diagnosis of acute endophthalmitis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Investigation of pharmacy A revealed multiple areas in which practices did not conform to United States Pharmacopeial Convention Chapter 797 standards for compounding sterile preparations or to recommended best practices for repackaging bevacizumab; these deficiencies might have contributed to bevacizumab contamination” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical decision-making around bevacizumab non-response
Photodynamic therapy and thermal laser photocoagulation
Historical role of verteporfin photodynamic therapy
“In 2000 photodynamic therapy with verteporfin (PDT-V) was approved by the United States' Food and Drug Administration for the treatment of subfoveal CNV due to AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PDT-V alone has been shown in a large number of cases to require retreatments every 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
National Eye Institute description of photodynamic therapy
Limitations of current therapies
Frequent injections and monitoring visits
“requires repeated and frequent intravitreal injections of the drug, which are necessary to maintain the therapeutic effect, frequent clinical visits to monitor efficacy and safety, and a significant financial burden associated with high drug costs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contamination risk specific to repackaged bevacizumab
“Investigation of pharmacy A revealed multiple areas in which practices did not conform to United States Pharmacopeial Convention Chapter 797 standards for compounding sterile preparations or to recommended best practices for repackaging bevacizumab; these deficiencies might have contributed to bevacizumab contamination” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response heterogeneity across agents and patients
Place in treatment, anticipated use, and care setting
First FDA-approved ophthalmic bevacizumab formulation
Manufacturer statement on positioning
Heterogeneity of treatment effect
Genetic modifiers of anti-VEGF response
“Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For both rs800292 and rs6677604, carriage of the A allele was protective and decreased the nAMD risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Knowledge-guided individualization
“Unraveling the association between AMD genetics and response to therapy could pave the way for personalized AMD treatment, with genetic variants serving as predictors of its outcome, treatment regimen, and dosage mode.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lesion and dosing-driven heterogeneity across agents
“aflibercept 2 mg, aflibercept 8 mg, bevacizumab 1.25 mg (off‐label or on‐label), brolucizumab 6 mg, faricimab 6 mg, ranibizumab 0.5 mg, and the corresponding biosimilars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One main underlying factor influencing visual outcomes is the average number of injections over time,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex-related heterogeneity in incidence and burden
Care management intervention strategies
Treat-and-extend regimens
“requires repeated and frequent intravitreal injections of the drug, which are necessary to maintain the therapeutic effect, frequent clinical visits to monitor efficacy and safety, and a significant financial burden associated with high drug costs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“monthly, monthly for the first three months followed by PRN, every eight weeks, quarterly cross‐over from monthly to PRN, and treat‐and‐extend protocols” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home optical coherence tomography as a safety net between visits
“Home-based optical coherence tomography (OCT) has emerged as a potential tool to bridge this surveillance gap by enabling frequent, patient-administered imaging between office visits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Persistent or recurring fluid was identified in 121 (65%) intervals, on average 32 days prior to the next office visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Home OCT monitoring provides adjunctive information to support early detection of fluid and may facilitate timely clinical evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Amsler grid self-monitoring between visits
Extended-interval dosing to reduce visit burden
Other product development or post-marketing obligations required by the FDA
Postmarketing commitment on reference standard qualification
Ongoing post-approval monitoring
Adverse experience and distribution reporting
Biological product deviation reporting
Expected outcomes of therapy
Vision stabilization and improvement with anti-VEGF therapy
Contrast with untreated natural history
“ranibizumab not only prevented loss of vision in nAMD treatment-naïve patients (the natural history for these patients), but also, and for the first time ever in this disease, that their vision could recover, as shown by the 7.2 letters gained on average in the ranibizumab 0.5 mg dose group (the dose subsequently marketed) versus an average loss of 10.4 letters by the sham group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote